Special Issue "Novel Biomarkers in Neurodegenerative Disorders"

A special issue of Metabolites (ISSN 2218-1989). This special issue belongs to the section "Endocrinology and Clinical Metabolic Research".

Deadline for manuscript submissions: closed (15 December 2022) | Viewed by 997

Special Issue Editors

1. Laboratory of NeuroImaging, USC Stevens Neuroimaging and Informatics Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
2. Neuroscience Graduate Program, University of Southern California, Los Angeles, CA, USA
Interests: dementia; stroke; Alzheimer’s disease; blood–brain barrier; cerebrovasculature; perivascular spaces; magnetic resonance imaging
Department of Life Sciences, University of Modena and Reggio Emilia, 41121 Modena, MO, Italy
Interests: metabolomics; mass spectrometry; psychiatric diseases; neuroinflammation; kynurenine pathway

Special Issue Information

Dear Colleagues,

In the last decade, the advancement in neuroimaging and omics fields, including metabolomics, genomics, transcriptomics, proteomics, lipidomics and radiomics, has made it possible to significantly increase the knowledge about the biological mechanisms underlying healthy aging and neurodegenerative diseases such as Alzheimer’s disease and other types of dementia. In particular, the integration of multiple omics approaches made it possible to gain insights into the metabolic processes characterizing specific stages of the investigated diseases, and how they are affected by certain treatments. From a clinical perspective, this knowledge is particularly important not only for the development of strategies for the treatment and prevention of these pathologies, but also for the identification of biomarkers for neurodegenerative diseases, which may ultimately lead to the optimization of the current diagnostic frameworks and clinical management of patients.

This Special Issue aims to include preclinical, population-based, and clinical studies that investigate biological processes underlying neurodegenerative diseases for the identification of novel biomarkers. Investigations integrating different types of technologies with one or more omics approaches are particularly encouraged. Methodological articles presenting novel strategies for biomarker discoveries and validation will also be highly considered.

Dr. Giuseppe Barisano
Dr. Silvia Alboni
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Metabolites is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • neurodegenerative diseases
  • Alzheimer’s disease
  • dementia
  • Parkinson’s disease
  • neuroimaging
  • metabolomics
  • proteomics
  • lipidomics
  • transcriptomics
  • genomics

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


Biomarkers of Drug Resistance in Temporal Lobe Epilepsy in Adults
Metabolites 2023, 13(1), 83; https://doi.org/10.3390/metabo13010083 - 04 Jan 2023
Cited by 1 | Viewed by 714
Temporal lobe epilepsy (TLE) is the most common type of focal epilepsy in adults. Experimental and clinical data indicate that neuroinflammation and neurodegeneration accompanying epileptogenesis make a significant contribution to the chronicity of epilepsy and the development of drug resistance in TLE cases. [...] Read more.
Temporal lobe epilepsy (TLE) is the most common type of focal epilepsy in adults. Experimental and clinical data indicate that neuroinflammation and neurodegeneration accompanying epileptogenesis make a significant contribution to the chronicity of epilepsy and the development of drug resistance in TLE cases. Changes in plasma and serum concentrations of proteins associated with neuroinflammation and neurodegeneration can be predictive biomarkers of the course of the disease. This study used an enzyme-linked immunosorbent assay of the following plasma proteins: brain-derived neurotrophic factor (BDNF), tumor necrosis factor alpha (TNFa), and high-mobility group protein B1 (HMGB1) in patients with mesial TLE to search for biomarkers of the disease. The objective of the study was to examine biomarkers of the neuroinflammation and neurodegeneration of plasma: BDNF, TNFa, and HMGB1. The aim of the study was to identify changes in the concentration of circulating pro-inflammatory and neurotrophic factors that are prognostically significant for the development of drug resistance and the course of TLE. A decrease in the concentration of BDNF, TNFa, and HMGB1 was registered in the group of patients with TLE compared with the control group. A significant decrease in the concentration of HMGB1 in patients with drug-resistant TLE was observed. Aberrations in plasma concentrations of BDNF, TNFa, and HMGB1 in patients with TLE compared with the controls have been confirmed by earlier studies. A decrease in the expression of the three biomarkers may be the result of neurodegenerative processes caused by the long course of the disease. The results of the study may indicate the acceptability of using HMGB1 and TNFa as prognostic biological markers to indicate the severity of the disease course and the risk of developing drug resistance. Full article
(This article belongs to the Special Issue Novel Biomarkers in Neurodegenerative Disorders)
Show Figures

Figure 1

Back to TopTop